PPARγ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 99-106

  Zou, Wei ^a   Liu, Xiangguo ^a   Yue, Ping ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; c FLIP; Death receptor 5; Lung cancer cells; PPAR ligands; TRAIL

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; CIGLITAZONE; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PIRINIXIC ACID; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; CFLAR PROTEIN, HUMAN; LIGAND; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; CELL CULTURE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; LUNG TUMOR; METABOLISM; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; LIGANDS; LUNG NEOPLASMS; PPAR GAMMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33847169497     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3555     Document Type: Article

References (24)

1. Almasan A, Ashkenazi A. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14:337-48.
2. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4:333-9.
3. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281:1305-8.
4. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: Targeting and activation of death receptors. Cytokine Growth Factor Rev 2005; 16:55-76.
5. Wajant H. Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy. Mol Interv 2003; 3:124-7.
6. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005; 25:31-58.
7. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190-5.
8. Sun SY. Chemopreventive agent-induced modulation of death receptors. Apoptosis 2005; 10:1203-10.
9. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001; 7:395-400.
10. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 2004; 4:465-77.
11. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003; 9:1-9.
12. Li MY, Lee TW, Yim AP, Chen GG. Function of PPARgamma and its ligands in lung cancer. Crit Rev Clin Lab Sci 2006; 43:183-202.
13. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 2002; 8:1206-12.
14. Avis I, Martinez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine JL. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005; 65:4181-90.
15. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277:22320-9.
16. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O, Roth W. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006.
17. Nakata S, Yoshida T, Shiraishi T, Horinaka M, Kouhara J, Wakada M, Sakai T. 15-Deoxy-D elta12,14-prostaglandin J(2) induces death receptor 5 expression through mRNA stabilization independently of PPARgamma and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 2006; 5:1827-35.
18. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, Heyman RA, Teng M, Chandraratna RA, Shudo K, Hong WK, Lotan R. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human nonsmall cell lung carcinoma cells. Cancer Res 1997; 57:4931-9.
19. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, Lotan R. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human nonsmall cell lung carcinoma cells. Oncogene 1999; 18:2357-65.
20. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96:1769-80.
21. Sun SY, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000; 60:6537-43.
22. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human nonsmall cell lung carcinoma cells by the novel synthetic retinoid CD437. J Cell Physiol 1997; 173:279-84.
23. Goke R, Goke A, Goke B, El-Deiry WS, Chen Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion 2001; 64:75-80.
24. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, Lee EJ, Jameson JL, Jordan VC, Cryns VL. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280:6742-51.